BioSpace News Archive

Drug Development

Extended Follow-up Phase 3 Data Underscore Sustained Efficacy and Safety of IMBRUVICA® (ibrutinib) in the Treatment of Chronic Lymphocytic Leukemia (CLL)

Follow-up data from Phase 3 E1912 study (abstract #33) evaluating IMBRUVICA in combination with rituximab versus standard chemoimmunotherapy (FCR) showed that previously untreated patients (aged 70 or younger) with CLL lived longer and with sustained benefit, with superior progression-free survival and overall survival - two critical measures in oncology treatment success

December 7, 2019
·
17 min read
BioCapital

CALQUENCE Significantly Prolonged the Time Patients Lived Without Disease Progression or Death in Previously Untreated Chronic Lymphocytic Leukemia

Full results from Phase III ELEVATE TN trial showed 93% of patients on CALQUENCE combined with obinutuzumab vs. 47% of patients on chlorambucil plus obinutuzumab remained free of disease progression or death at 24 months

December 7, 2019
·
16 min read
Sierra Oncology Reports Decreased Transfusion Requirements for Patients Treated with Momelotinib Directly Compared to Ruxolitinib at ASH Annual Meeting

New analyses of Phase 3 data highlighting momelotinib’s meaningful anemia benefits in myelofibrosis presented in a poster at the 61st American Society of Hematology Annual Meeting

December 7, 2019
·
11 min read
Drug Development

Sangamo and Pfizer Announce Updated Phase 1/2 Results Showing Sustained Increased Factor VIII Activity Through 44 Weeks Following SB-525 Gene Therapy Treatment

The first two patients treated with the 3e13 vg/kg dose achieved stable Factor VIII (FVIII) levels demonstrating durability in the normal range through 44 and 37 weeks, respectively

December 7, 2019
·
12 min read
Biotech Bay

Genentech Announces New Data on Novel Cd20-cd3 Bispecific Cancer Immunotherapies in People With Difficult-to-Treat Lymphomas

Mosunetuzumab data to be presented at the American Society of Hematology 2019 Annual Meeting Plenary Scientific Session demonstrate durable complete responses in people with relapsed or refractory non-Hodgkin’s lymphoma

December 7, 2019
·
13 min read
Drug Development

Epizyme Presents Updated Phase 2 Data at the 2019 ASH Annual Meeting Supporting Planned Tazemetostat NDA Submission for Follicular Lymphoma

NDA Submission for Accelerated Approval of Tazemetostat for Patients with Relapsed or Refractory Follicular Lymphoma on Track for December 2019

December 7, 2019
·
8 min read
Aptose Presents Highlights From Corporate Event At ASH

Aptose Biosciences Inc. released highlights from a corporate event and clinical update held at the 61st American Society of Hematology Annual Meeting and Exposition in Orlando, FL.

December 7, 2019
·
7 min read
Drug Development

Stoke Therapeutics Presents Preclinical Data From Studies of STK-001 That Showed Improvements in Survival and Reductions in Seizure Frequency in a Mouse Model of Dravet Syndrome

New data from electroencephalography (EEG) recordings showed 76% of Dravet syndrome (DS) mice treated with STK-001 were seizure free compared to 48% of placebo-treated mice

December 7, 2019
·
9 min read
Drug Development

Cellular Biomedicine Group Presents First Clinical Data of IIT Phase 1 Trial of C-CAR088, a Novel BCMA CAR-T, at the 61st Annual Meeting of the American Society of Hematology

Five Patients were included in the analysis; all five patients showed clinical improvement in as early as two weeks

December 7, 2019
·
6 min read
BioMidwest

More than Seven-Year Analysis of Early Treatment with IMBRUVICA® (ibrutinib) Monotherapy Showed Improved Progression-Free Survival in Patients with Mantle Cell Lymphoma (MCL) that Relapsed or Were Unresponsive to Prior Regimen

With extended follow-up of up to 7.5 years, treatment with IMBRUVICA early on in therapy demonstrated higher rates of progression-free survival and complete response

December 7, 2019
·
14 min read